Literature DB >> 11511418

Nematocidal activities of thiabendazole and ivermectin against the larvae of Strongyloides ratti and S. venezuelensis.

T Satou1, M Koga, K Koike, I Tada, T Nikaido.   

Abstract

With the aim of developing therapeutic agents for strongyloidosis, the disease caused by infection with Strongyloides stercoralis, we established a novel assay technique using S. ratti and S. venezuelensis as models for S. stercoralis. The newly developed assay technique was found to more accurately represent treatment-induced larval paralysis than existing assays. Our method uses paper disks impregnated with the test solution, which even allows materials that are sparingly soluble in water to be tested. An inverted microscope was used to observe the larval states, and these states were recorded using a digital camera. We observed the activities of ivermectin and thiabendazole against larvae and calculated larval motility and velocity. These two factors were then combined to determine the overall viability of larvae at selected concentrations. The activities of the anthelmintics were compared by calculating the concentrations at which 50% viability was demonstrated, or in other words, the concentration at which paralysis was caused in 50% of the individuals (50% paralysis concentration; PC(50)). Evaluations after 24h of exposure yielded the following reproducible PC(50) values for ivermectin and thiabendazole, respectively: S. ratti, 2.4 and 140 microM; and S. venezuelensis, 2.3 and 190 microM. After treatment with ivermectin, there was a tendency for larval motility to be greater than that of the controls at low concentrations, a result that might be associated with its mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511418     DOI: 10.1016/s0304-4017(01)00472-1

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  4 in total

1.  Non-oral treatment with ivermectin for disseminated strongyloidiasis.

Authors:  Dahlene N Fusco; Jennifer A Downs; Michael J Satlin; Meera Pahuja; Liz Ramos; Philip S Barie; Lawrence Fleckenstein; Henry W Murray
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

2.  Failure of ivermectin per rectum to achieve clinically meaningful serum levels in two cases of Strongyloides hyperinfection.

Authors:  Isaac I Bogoch; Kamran Khan; Howard Abrams; Caroline Nott; Elizabeth Leung; Lawrence Fleckenstein; Jay S Keystone
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

3.  Update on strongyloidiasis in the immunocompromised host.

Authors:  Luis A Marcos; Angélica Terashima; Marco Canales; Eduardo Gotuzzo
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

4.  Dissemination of Strongyloides stercoralis in a patient with systemic lupus erythematosus after initiation of albendazole: a case report.

Authors:  Catherine J Hunter; Mikael Petrosyan; Morris Asch
Journal:  J Med Case Rep       Date:  2008-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.